11 completed, 2 terminated, 1 active not recruiting, 1 unknown. 9 Phase 1, 5 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 9 | Completed 5, Active not recruiting 1, Terminated 1, Unknown 1, Withdrawn 1 |
| Phase 2 | 5 | Completed 4, Terminated 1 |
| Phase 3 | 1 | Completed 1 |
Follow Lymphoma, Malignant: new trials by email Literature Review of Lymphoma, Malignant trials Research Report on Lymphoma, Malignant
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy of Patient Management for Lymphoma Diagnosed at Nimes University Hospital From 1999 to 2018. DVR-Lym-Nim Lymphoma, Malignant | Terminated | Centre Hospitalier Universitaire de Nīmes | 136 | 2024-01-22 | 2026-09-09 | |
| A Study to Evaluate the Effect of Food on the Pharmacokinetics (PK) of TAK-659 in Participants With Advanced Solid Tumor TAK-659 - Lymphoma, Malignant, Advanced Solid Neoplasms | Phase 1 | Withdrawn | Calithera Biosciences, Inc | 2018-02-28 | 2023-02-08 | |
| Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG Fludarabine, Busulfan, Rabbit ATG - Leukemia, Lymphoid, Leukemia, Myeloid | Phase 1 | Completed | Dartmouth-Hitchcock Medical Center | 20 | 2016-09-06 | 2023-10-18 |
| DS-3201b in Participants With Lymphomas DS-3201b - Lymphoma, Malignant, Non-hodgkin Lymphoma | Phase 1 | Active not recruiting | Daiichi Sankyo Co., Ltd. | 100 | 2016-03-31 | 2026-04-28 |
| A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors ASN002 Dose Escalation, ASN002 RD - Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell | Phase 1 / Phase 2 | Terminated | Asana BioSciences | 51 | 2015-05-01 | 2023-06-07 |
| Open-Label, Non Randomized Phase 2 Study With Safety Run-In bimiralisib - Lymphoma, Malignant | Phase 2 | Completed | PIQUR Therapeutics AG | 53 | 2015-05-01 | 2019-09-06 |
| Clinic Study of 18F-Al-NOTA-PRGD2 in Cancer Diagnostics 18F-Al-NOTA-PRGD2 PET/CT - Tumors, Carcinoma, Bronchogenic | Phase 1 | Unknown | Wuxi No. 4 People's Hospital | 200 | 2012-01-01 | 2017-03-10 |
| A Study of Enzastaurin in Chinese Patients With Advanced and/or Metastatic Solid Tumors or Lymphoma Enzastaurin - Solid Tumor, Lymphoma, Malignant | Phase 1 | Completed | Eli Lilly and Company | 26 | 2011-11-01 | 2020-10-12 |
| A Drug Interaction Study to Assess the Effect of LY317615 on the Metabolic Pathway of Warfarin warfarin, enzastaurin - Solid Tumor, Lymphoma, Malignant | Phase 1 | Completed | Eli Lilly and Company | 13 | 2011-08-01 | 2020-07-01 |
| A Phase 1 Study of SB1518 for the Treatment of Advanced Lymphoid Malignancies SB1518 - Lymphoma, Malignant, Hodgkin's Lymphoma | Phase 1 | Completed | S*BIO | 35 | 2008-07-01 | 2012-04-20 |
| Rituximab and Involved Field Radiotherapy in Early Stage Follicular Lymphoma Rituximab - Lymphoma, Malignant | Phase 2 | Completed | Klaus Herfarth, MD | 85 | 2008-03-01 | 2020-01-06 |
| Multi-day Doses in Prevention of Nausea and Emesis Palonosetron, Aprepitant, Dexamethasone - Myeloma, Plasma-Cell, Lymphoma, Malignant | Phase 2 | Completed | University of Kansas Medical Center | 20 | 2007-10-01 | 2017-03-09 |
| Myeloablative Hematopoietic Progenitor Cell Transplantation (HPCT) for Pediatric Malignancies Myeloablative Chemotherapy Regimen for Lymphoid Malignancies or Cord Blood Unit Recipients, Myeloablative Chemotherapy Regimen for Non-Cord Blood Unit Recipients with Myeloid Malignancies, Hematopoietic Progenitor Cell Transplantation (HPCT) - Leukemia, Myelogenous, Chronic, Leukemia, Lymphoblastic, Acute | Completed | Ann & Robert H Lurie Children's Hospital of Chicago | 81 | 2007-03-26 | 2025-03-07 | |
| Dosing and Safety Study of E7820 in Patients With a Malignant Solid Tumor or Lymphoma E7820 - Neoplasms, Lymphoma, Malignant | Phase 1 | Completed | Eisai Inc. | 37 | 2004-01-01 | 2014-12-23 |
| Low-Intensity Preparation and Allogeneic Transplant in Patients With Cancers of the Blood Reduced intensity conditioning with allogeneic transplant - Myeloma, Plasma-Cell, Lymphoma, Malignant | Phase 2 | Completed | University of Michigan Rogel Cancer Center | 60 | 2000-03-01 | 2012-08-09 |
| Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia (PN-152,243)/PN-196,444 - Neoplasms, Thrombocytopenia | Phase 3 | Completed | Pfizer | 180 | 1999-12-01 | 2006-11-09 |
Lymphoma (16) · Neoplasms (5) · Multiple Myeloma (4) · Lymphoma, B-Cell (3) · Lymphoma, Non-Hodgkin (3) · Myelodysplastic Syndromes (3) · Waldenstrom Macroglobulinemia (3) · Lymphoma, Large B-Cell, Diffuse (2) · Lymphoma, T-Cell, Peripheral (2) · Primary Myelofibrosis (2) · Breast Neoplasms (1) · Carcinoma, Bronchogenic (1) · Graft vs Host Disease (1) · Head and Neck Neoplasms (1) · Hodgkin Disease (1)
Hemic and Lymphatic Diseases (16) · Immune System Diseases (16) · Immunoproliferative Disorders (16) · Lymphatic Diseases (16) · Lymphoproliferative Disorders (16) · Neoplasms by Histologic Type (16) · Neoplasms (11) · Hematologic Diseases (8) · Blood Protein Disorders (5) · Cardiovascular Diseases (5) · Hemorrhagic Disorders (5) · Hemostatic Disorders (5) · Neoplasms, Plasma Cell (5) · Paraproteinemias (5) · Vascular Diseases (5)
enzastaurin (2) · 11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (1) · Aprepitant (1) · Busulfan (1) · Calcium Dobesilate (1) · Dexamethasone (1) · Methotrexate (1) · N-(3-cyano-4-methyl-1H-indol-7-yl)-3-cyanobenzene-sulfonamide (1) · Palonosetron (1) · Phosphatidylinositol 3-Kinase (1) · Rituximab (1) · TAK-659 (1) · Transplantation, Homologous (1) · Warfarin (1) · fludarabine (1)
Eli Lilly and Company (2) · Ann & Robert H Lurie Children's Hospital of Chicago (1) · Asana BioSciences (1) · Calithera Biosciences, Inc (1) · Centre Hospitalier Universitaire de Nīmes (1) · Daiichi Sankyo Co., Ltd. (1) · Dartmouth-Hitchcock Medical Center (1) · Eisai Inc. (1) · Klaus Herfarth, MD (1) · PIQUR Therapeutics AG (1) · Pfizer (1) · S*BIO (1) · University of Kansas Medical Center (1) · University of Michigan Rogel Cancer Center (1) · Wuxi No. 4 People's Hospital (1)
United States (11) · France (3) · Argentina (2) · China (2) · Bosnia and Herzegovina (1) · Germany (1) · Israel (1) · Japan (1) · Mexico (1) · Serbia (1) · United Kingdom (1)
Anas Younes, M.D. (1) · Carole Soussain (1) · Danijela Mandic (1) · David Cunningham (1) · Giulino Roth (1) · Graham Collins (1) · Ivan Tijanic (1) · Jantien Wanders, M.D. (1) · John E. Levine, MS MD (1) · Kenneth Meehan, MD (1) · Klaus Herfarth, MD (1)
PMID 16818691, PMID 18077538, PMID 22965964, PMID 26942463, PMID 31723798, PMID 38967722, PMID 39486432, PMID 41150706, PMID 41258689